SplitJul 20, 2026, 04:31 PM
Calidi Biotherapeutics Announces 1-for-16 Reverse Stock Split
AI Summary
Calidi Biotherapeutics, Inc. announced a 1-for-16 reverse stock split of its outstanding common shares, effective when the NYSE American market opens on July 31, 2026. The company aims to optimize market dynamics, broaden investor appeal, and align trading conditions. The reverse stock split was approved by stockholders on June 12, 2026, and the Board of Directors approved the specific ratio on July 15, 2026. Fractional shares will be rounded up, and proportionate adjustments will be made to outstanding options, warrants, and equity plans.
Key Highlights
- Calidi Biotherapeutics will effect a 1-for-16 reverse stock split.
- Common stock expected to commence trading on a split-adjusted basis on July 31, 2026.
- New CUSIP number for the common stock will be 320703 507.
- Stockholders approved the reverse stock split on June 12, 2026.
- Board of Directors approved the 1-for-16 ratio on July 15, 2026.
- Fractional shares will be rounded up to the nearest whole share.
- Equiniti Trust Company, LLC appointed as the exchange agent.
Price Impact
More from CLDI